Buff your life with research
and the right peptides.

• Lower end100-200 mcg each, combined with CJC-1295 No DACAnecdotal1

  The classic 'saturation dose' combo biohackers inject 2-3 times daily (fasted AM, post-workout, pre-bed) for growth-hormone pulses.

• Common pattern200-300 mcg, 1-2 times dailyAnecdotal1

  The standard community dose for sleep and recovery, injected fasted — most stack it with CJC-1295 No DAC rather than running it solo.

• Higher end200-300 mcg, 2-3 times dailyAnecdotal1

  Higher-frequency 'body recomposition' protocol reported by those chasing body-composition change, with strict fasting windows around each injection.

Ipamorelin is not FDA-approved. Community dosing and the CJC-1295 combination have not been validated in controlled trials, and most users stack it with other peptides, making attribution difficult.

• 1 Peptide Protocol Wiki: Ipamorelin community protocols (200 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end100-200 mcg once daily, before bedAnecdotal1

  A simplified once-daily pre-bed protocol some run for anti-aging and general wellness, typically with a 5-days-on, 2-days-off rhythm.

• Common pattern100 mcg (combined with 100 mcg Ipamorelin), 2-3 times dailyAnecdotal1

  The community 'saturation dose' — biohackers believe 100 mcg fully occupies the GHRH receptor, so higher single doses add little. Nearly always paired with Ipamorelin.

• Higher end200 mcg (with 200 mcg Ipamorelin) post-workoutAnecdotal1

  Targeted post-exercise dosing athletes use to ride the natural growth-hormone response to training.

CJC-1295 No DAC is not FDA-approved, and the 100 mcg 'saturation dose' is community-derived, not from dose-response studies. Do not transfer doses between DAC and No DAC forms — they have very different half-lives. FDA flags limited safety data and serious adverse-event reports for compounded CJC-1295.

• 1 Peptide Protocol Wiki: CJC-1295 No DAC community protocols (180 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end0.5-1 mg, 3-5 times per weekAnecdotal1

  A lower-frequency maintenance protocol some use for long-term mitochondrial support rather than daily dosing.

• Common pattern1-5 mg once dailyAnecdotal1

  The community anti-aging dose range, adapted from rough allometric scaling of mouse studies — far below the 40 mg daily FDA-labeled Barth syndrome dose.

Forzinity is FDA-approved only for Barth syndrome (a rare genetic mitochondrial disorder). Community anti-aging use in healthy people is off-label and extrapolated from disease-state data. Whether community doses achieve meaningful mitochondrial effects in healthy users is unknown.

• 1 Peptide Protocol Wiki: SS-31 community protocols (30 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end10 mg once weekly before exerciseAnecdotal1

  A single weekly injection some use before endurance work, aiming for added mitochondrial signaling.

• Common pattern5-10 mg, 2-3 times weeklyAnecdotal1

  The standard community dose, split across the week and frequently timed before endurance exercise — framed as an 'exercise mimetic,' not a replacement for training.

MOTS-c has never been tested in human clinical trials — every protocol is extrapolated from mouse data. It is WADA-prohibited for sport. The 'exercise replacement' framing is misleading; it activates similar pathways to exercise but cannot replicate them.

• 1 Peptide Protocol Wiki: MOTS-c community protocols (40 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end100-200 mcg once dailyAnecdotal12

  A community 'maintenance' dose some self-experimenters report for general recovery; it sits near the rat-derived human-equivalent estimate.

• Common pattern250-500 mcg once or twice dailyAnecdotal12

  The standard healing protocol biohackers swap in most often for tendon, ligament, and muscle injuries, usually injected close to the injury.

BPC-157 is not FDA-approved and is WADA-banned for sport. Community doses are extrapolated from rat data, not validated in human trials. The FDA flags immunogenicity and limited safety data, and long-term human safety is unknown.

• 1 Peptide Protocol Wiki: BPC-157 community protocols (150 reports)
• 2 Jay Campbell: BPC-157 dosage guide (practitioner-community)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end2 mg twice weeklyAnecdotal1

  A conservative healing dose some use for minor injuries and joint discomfort without a distinct loading phase.

• Common pattern4-8 mg per week (loading), then 2-4 mg per week (maintenance)Anecdotal1

  The community-standard loading-then-maintenance structure biohackers built for tendon, ligament, and systemic repair — usually stacked with BPC-157 as the Wolverine protocol.

• Higher end5-10 mg, 2-3 times weeklyAnecdotal1

  An aggressive post-surgical or severe-injury protocol a minority report — higher than most community members use.

TB-500 (a 7-amino-acid fragment) is not the same molecule as the full-length Thymosin Beta-4 used in clinical research, so trial results may not transfer. The loading/maintenance structure is community-derived, with no basis in published human studies. TB-500 is not FDA-approved.

• 1 Peptide Protocol Wiki: TB-500 community protocols (120 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower endAbout 0.5 mg subcutaneously per administrationAnecdotal13

  A sub-milligram subcutaneous dose community planners describe as a conservative start to gauge cognitive response and tolerance before stepping up.

• Common pattern1 mg subcutaneously, 2-3 mornings per weekAnecdotal12

  The standard community subcutaneous protocol — reconstituted from a research vial, injected in the morning, cycled 8 weeks on / 8 weeks off. Reported as the BDNF 'sweet spot' without overdriving stimulation.

• Higher end2 mg subcutaneously once dailyAnecdotal12

  An acute-focus daily subcutaneous protocol some run during demanding cognitive stretches — offset by overstimulation and sleep disruption if dosed late.

Semax is approved in Russia (for stroke recovery and cognitive disorders) but not by the FDA or EMA. Published human data for subcutaneous use is sparse. Semax was on the FDA 503A Category 2 list (immunogenicity concern) until the nomination was withdrawn in April 2026 — removal is procedural, not a safety clearance. Overstimulation and sleep disruption are reported, especially with late-day dosing.

• 1 Peptide Protocol Wiki: Semax community protocols (130 reports)
• 2 The Peptide Catalog: Semax 1mg SubQ, 2-3x/week protocol
• 3 Peptide Dosing Protocols: Semax SubQ research-context guide

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end500 mcg subcutaneously, 2-3 mornings per weekAnecdotal2

  A starter subq dose some begin at to gauge anxiolytic response before stepping up to the standard 1 mg, still cycled 8 weeks on / 8 off.

• Common pattern1 mg subcutaneously, 2-3 mornings per weekAnecdotal2

  The standard community subq protocol — reconstituted from a research vial, injected in the morning, cycled 8 weeks on / 8 weeks off for anxiety reduction without sedation.

• Higher end2 mg subcutaneously once dailyAnecdotal2

  An acute-anxiolysis daily subq protocol a minority run during high-stress stretches — offset by mild stimulating effects if dosed late, so the community keeps it mornings.

Selank is approved in Russia as an anxiolytic but not by the FDA or EMA. The subcutaneous route biohackers use has not been studied in clinical settings. Self-reported anxiety reduction is highly placebo-susceptible.

• 1 Peptide Protocol Wiki: Selank community protocols (120 reports)
• 2 The Peptide Catalog: Selank 1mg SubQ, 2-3x/week protocol

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end1 mg subcutaneously once dailyAnecdotal12

  A conservative entry subq dose some start with for collagen and skin-quality support, often 3-5 times per week rather than daily, before settling at the community standard.

• Common pattern1.7-2 mg subcutaneously once dailyAnecdotal21

  The community-standard subq protocol — 1.7 mg/day is the most-cited anchor dose, injected in the morning and cycled 8 weeks on / 8 weeks off for systemic collagen, skin, and recovery support.

• Higher end3 mg subcutaneously once dailyAnecdotal2

  An advanced subq dose a minority push to for more aggressive tissue-repair goals, still cycled 8 weeks on / 8 weeks off. Copper accumulation is a theoretical concern at this level.

Injectable GHK-Cu for cosmetic or systemic use has limited clinical validation. Copper overload is a theoretical concern with high-dose or long-term injection, and product quality varies, especially for injectable preparations.

• 1 Peptide Protocol Wiki: GHK-Cu community protocols (90 reports)
• 2 The Peptide Catalog: GHK-Cu 1.7mg/day injectable protocol

What biohackers report — descriptive, not dosing guidance or medical advice.

• Common pattern200-500 mcg once dailyAnecdotal1

  The standard community anti-inflammatory subcutaneous dose for gut-barrier and reactive-skin goals, usually started at the low end and run for 4-8 week cycles.

KPV has no human clinical trial data. The wide community dose range signals how little is established. It acts independently of melanocortin receptors, so tanning or appetite effects some expect from its parent alpha-MSH do not apply.

• 1 Peptide Protocol Wiki: KPV community protocols (40 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end0.5-4 mg once weeklyAnecdotal1

  A conservative-start protocol some use to assess tolerance, escalating more slowly than the clinical schedule.

• Common pattern1-12 mg once weekly, escalating every 4 weeksAnecdotal1

  The community mirrors the Phase 2 trial escalation (1 → 2 → 4 → 8 → 12 mg), chasing the ~24% weight loss reported at 48 weeks — but from research-grade product of unverified potency.

• Higher end4-8 mg once weekly (maintenance)Anecdotal1

  Where some community members settle for maintenance — enough appetite suppression without pushing to the 12 mg maximum.

Retatrutide is investigational — not FDA-approved, only available through Phase 3 trials or unverified research-grade vendors. The glucagon-receptor component raises heart-rate and metabolic-monitoring concerns the community cannot self-manage. Community reports cannot verify product authenticity.

• 1 Peptide Protocol Wiki: Retatrutide community protocols (100 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end2.5 mg once weekly, stepping up about every 4 weeksFDA-labeled1

  The FDA-labeled starting titration the community follows almost universally; compounded users mirror it from multi-dose vials.

• Common pattern7.5-10 mg once weeklyAnecdotal23

  Where most community members actually settle for maintenance — enough appetite suppression with fewer GI side effects than the maximum dose.

• Higher end15 mg once weeklyFDA-labeled1

  The highest FDA-labeled maintenance dose, reached after gradual 2.5 mg step-ups. Community results usually sit below the trial ceiling at this dose.

Tirzepatide carries a boxed warning for thyroid C-cell tumors (rodent data) and risks including pancreatitis and gallbladder disease. Compounded tirzepatide is not FDA-approved; the FDA confirmed no shortage exists and has restricted compounding.

• 1 FDA Zepbound prescribing information, 2026
• 2 Peptide Protocol Wiki: Tirzepatide community protocols (400 reports)
• 3 GLP3 Planner: Tirzepatide Reddit roundup (r/tirzepatidecompound, r/Zepbound)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end50 mg subcutaneously, 2-3 times weeklyAnecdotal21

  Some community members report working up to 50 mg over the first couple of weeks, using it to gauge tolerance and the 'NAD flush' before stepping up. That is what they report, not a recommended starting dose.

• Common pattern100 mg subcutaneously, 2-3 times weeklyAnecdotal2

  The standard community subq protocol — reconstituted at 100 mg/mL and injected in the morning, 2-3 times weekly, as the home-use alternative to clinic-based delivery.

• Higher end200 mg subcutaneously, twice weeklyAnecdotal2

  An advanced subq dose some run for a stronger energy ceiling: the full 200 mg at each of two weekly injections, limited by injection-site stinging and flush at faster delivery.

Whether direct subcutaneous NAD+ beats cheaper precursor supplements is actively debated and unresolved. Long-term safety of repeated high-dose NAD+ injection is not established, and immediate energy reports partly reflect placebo and setting.

• 1 Peptide Protocol Wiki: NAD+ community protocols (200 reports)
• 2 The Peptide Catalog: NAD+ 100mg SubQ, 2-3x/week protocol

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end100-250 mcg, 3 times per weekAnecdotal1

  An intermittent protocol some use to avoid the rebound insomnia a few report after several weeks of daily use.

• Common pattern100-200 mcg once daily before bedAnecdotal1

  The standard community sleep protocol — most often described as deepening sleep rather than forcing onset. Some report next-day grogginess above 300 mcg.

• Higher end250-500 mcg once daily before bedAnecdotal1

  A higher-dose protocol for severe sleep issues — offset by reports of next-day drowsiness, so the community generally starts low.

DSIP research is dated and limited, and community subcutaneous doses are far lower than the doses used in the old research literature. Rebound insomnia after stopping is reported. Long-term safety of repeated use is unknown.

• 1 Peptide Protocol Wiki: DSIP community protocols (80 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Common pattern5 mg subcutaneously once dailyAnecdotal21

  The community-convention subq dose — run as a 10-20 day course, injected in the morning, following the Khavinson bioregulator paradigm. Not a trial dose; shaped by the common 10 mg vial format.

• Higher end10 mg subcutaneously once dailyAnecdotal2

  The upper community range — a full common 10 mg vial (half of our 20 mg vial) in one injection, run for the same short 10-20 day course. Unvalidated; no human trial supports this or any Pinealon dose.

Pinealon has a very thin evidence base — mostly in vitro cell-culture work from a single Russian research group. The Khavinson peptide-bioregulator paradigm has not been validated in large-scale trials. Effects users report are subtle and difficult to separate from placebo.

• 1 Peptide Protocol Wiki: Pinealon community protocols (35 reports)
• 2 The Peptide Catalog: Pinealon dosing (community convention)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end1.0-2.0 mg (off-label, often with a PDE5 inhibitor)Anecdotal1

  The off-label male protocol biohackers discuss most, frequently stacked with sildenafil or tadalafil — a combination with some clinical-trial support.

• Common pattern0.5-1.0 mg, on-demandAnecdotal1

  The community-derived lower dose many landed on to curb the nausea that hits roughly 40% of users at the full 1.75 mg label dose — reported as still effective for libido and arousal.

• Higher end1.75 mg, on-demandAnecdotal1

  The FDA-labeled Vyleesi dose (1.75 mg) that the community treats as the ceiling, capped at 8 doses per month — most biohackers stay below it to limit nausea.

PT-141 (bremelanotide / Vyleesi) is FDA-approved only for premenopausal HSDD — male use for ED is entirely off-label. Nausea affects ~40% at the labeled dose. Blood-pressure changes can occur; it is not recommended for uncontrolled hypertension or cardiovascular disease.

• 1 Peptide Protocol Wiki: PT-141 community protocols (150 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end1 mg once dailyAnecdotal1

  A half-dose protocol new users run to assess tolerance before stepping up to the full 2 mg.

• Common pattern2 mg once dailyAnecdotal1

  The community mirrors the FDA-labeled Egrifta dose (2 mg) for off-label visceral-fat reduction — injected abdominally before bed, knowing fat rebounds after stopping.

• Higher end1-2 mg, 5 days per weekAnecdotal1

  A reduced-frequency maintenance protocol some use long-term, accepting slower progress to lower cost and injection frequency.

Egrifta is FDA-approved only for HIV-associated lipodystrophy — community use for general visceral fat is off-label. Clinical data shows visceral fat rebounds after stopping, so community users expecting permanent results from a short cycle are disappointed.

• 1 Peptide Protocol Wiki: Tesamorelin community protocols (100 reports)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end0.1-0.25 mg daily for the first few daysAnecdotal21

  A small test dose many start with for the first 2-3 days to see how bad the nausea and flushing get before moving up. Often injected at bedtime to sleep through the worst of it.

• Common pattern0.5 mg daily to load, then 0.5 mg 1-2x weeklyAnecdotal21

  The most-reported community pattern: 500 mcg daily for about 2-3 weeks until the desired color shows, then the same dose once or twice a week to hold it. Not a trial dose; no study has tested this schedule.

Melanotan II is not approved anywhere. The FDA treats it as an unapproved drug, and regulators in Australia and the UK have warned against tanning injections. It darkens moles and freckles, which can hide changes that signal melanoma; dermatologists advise skin checks. Products are unregulated, so purity and dose are uncertain.

• 1 Peptide Protocol Wiki: Melanotan-2 community protocols (500 reports)
• 2 The Peptide Catalog: Melanotan-2 dosing (community convention)

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end5 mg once daily for about 20 daysAnecdotal12

  A common reading of the original Khavinson course: a smaller daily amount spread over more days. Not an approved dose.

• Common pattern5-10 mg once daily for 10-20 daysAnecdotal12

  The range those write-ups treat as the standard short course, repeated only a couple of times a year.

Epithalon is not an approved medicine. The course lengths come from the Khavinson research tradition and later clinic write-ups, not from a large independent trial. The price here is for one vial. Vial sizes vary, so a full course can take more than one vial.

• 1 Peptidepedia: Epithalon dosage protocols
• 2 TrimRX summary of the original 5-10 mg Khavinson courses

What biohackers report — descriptive, not dosing guidance or medical advice.

• Common pattern1.6 mg subcutaneously twice a weekClinically studied12

  This is the Zadaxin dose for chronic hepatitis B: 1.6 mg under the skin twice a week, with the days a few days apart, continued for months.

Zadaxin is approved for specific hepatitis treatment in some countries. It is not a general immune booster you can self-prescribe, and a research vial is not that medicine. People who are on purpose immunosuppressed, including many transplant patients, were called out as a group that should not use it unless a doctor decides the benefit outweighs the risk.

• 1 Singapore National Drug Formulary: Zadaxin 1.6 mg dosing
• 2 Zadaxin assessment report: 1.6 mg twice weekly for hepatitis B

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end0.25 mg once weekly for 4 weeksFDA-labeled1

  The Wegovy injection label starts every approved use here, for 4 weeks, before any increase.

• Common patternStep up every 4 weeks after 0.25 mgFDA-labeled1

  After the first 4 weeks the label raises the weekly injection about every 4 weeks. If a step is not tolerated, the label says to wait before raising it.

• Higher end2.4 mg once weeklyFDA-labeled12

  2.4 mg once weekly is the Wegovy injection strength listed as a maintenance product. The label reaches it only after the earlier steps.

This schedule is for the FDA-labeled Wegovy injection, prescribed and dispensed as that product. A research vial priced here is not a Wegovy pen, and the amount in the vial may not match the pen. Stomach side effects are why the label starts at 0.25 mg. Do not copy a high weekly dose on week one.

• 1 FDA Wegovy label: start 0.25 mg weekly, then escalate
• 2 Drugs@FDA: Wegovy includes a 2.4 mg injection strength

What biohackers report — descriptive, not dosing guidance or medical advice.

• Lower end10-20 IU once dailyAnecdotal1

  A smaller daily amount some people try when 24 IU feels like too much, usually for a few weeks.

• Common pattern20-40 IU once, often 24 IUAnecdotal12

  The amount community write-ups and many social-behavior studies both circle around. 24 IU is the figure named most often.

Hospital oxytocin for childbirth is a different product and a different dose. Nasal research sprays are not that IV bag. A research vial labeled in IU is easy to mis-measure because a single dose is a very small volume. Effects, when people notice them, are short.

• 1 Peptide Protocol Wiki: oxytocin community protocols
• 2 Peptide Protocol Wiki: oxytocin dosing, including 24 IU nasal research use

What biohackers report — descriptive, not dosing guidance or medical advice.